BRPI0814003A2 - Formulações de anticorpo - Google Patents

Formulações de anticorpo

Info

Publication number: BRPI0814003A2
Authority: BR; Brazil
Prior art keywords: antibody formulations; antibody; formulations
Prior art date: 2007-07-06

Application number

BRPI0814003-0A2A

Other languages

English (en)

Inventor

Charlene E Brisbane

Amol Sharad Ketkar

Ulla Tove Lashmar

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-06

Filing date

2008-07-03

Publication date

2015-02-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40228991&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0814003(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-07-03 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2008-07-03 Priority to BR122020026978-2A priority Critical patent/BR122020026978B1/pt

2015-02-03 Publication of BRPI0814003A2 publication Critical patent/BRPI0814003A2/pt

2021-06-15 Publication of BRPI0814003B1 publication Critical patent/BRPI0814003B1/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

BRPI0814003-0A 2007-07-06 2008-07-03 Formulações de anticorpo anti-cd20 BRPI0814003B1 (pt)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
BR122020026978-2A BR122020026978B1 (pt)	2007-07-06	2008-07-03	Uso de uma formulação de anticorpo anti-cd20

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US94822007P	2007-07-06	2007-07-06
US60/948,220		2007-07-06
PCT/US2008/069125 WO2009009407A1 (en)	2007-07-06	2008-07-03	Antibody formulations

Publications (2)

Publication Number	Publication Date
BRPI0814003A2 true BRPI0814003A2 (pt)	2015-02-03
BRPI0814003B1 BRPI0814003B1 (pt)	2021-06-15

Family

ID=40228991

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BR122020026978-2A BR122020026978B1 (pt)	2007-07-06	2008-07-03	Uso de uma formulação de anticorpo anti-cd20
BRPI0814003-0A BRPI0814003B1 (pt)	2007-07-06	2008-07-03	Formulações de anticorpo anti-cd20

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BR122020026978-2A BR122020026978B1 (pt)	2007-07-06	2008-07-03	Uso de uma formulação de anticorpo anti-cd20

Country Status (38)

Country	Link
US (2)	US20110020328A1 (pt)
EP (2)	EP2889310B1 (pt)
JP (1)	JP5529017B2 (pt)
KR (2)	KR20100038092A (pt)
CN (1)	CN101820912B (pt)
AR (2)	AR067455A1 (pt)
AU (1)	AU2008275278B2 (pt)
BR (2)	BR122020026978B1 (pt)
CA (1)	CA2692681C (pt)
CL (1)	CL2008001984A1 (pt)
CO (1)	CO6270340A2 (pt)
CR (1)	CR11249A (pt)
CY (2)	CY1118419T1 (pt)
DK (2)	DK2170388T3 (pt)
DO (1)	DOP2010000001A (pt)
EA (1)	EA017994B1 (pt)
ES (2)	ES2610821T3 (pt)
FR (1)	FR21C1040I1 (pt)
HK (2)	HK1141979A1 (pt)
HR (2)	HRP20170033T1 (pt)
HU (3)	HUE038501T2 (pt)
IL (1)	IL202950A (pt)
JO (1)	JO3219B1 (pt)
LT (3)	LT2889310T (pt)
MA (1)	MA31471B1 (pt)
MX (1)	MX2010000017A (pt)
NO (2)	NO2889310T3 (pt)
NZ (1)	NZ582250A (pt)
PE (1)	PE20090738A1 (pt)
PL (2)	PL2170388T3 (pt)
PT (2)	PT2170388T (pt)
SI (2)	SI2889310T1 (pt)
TR (1)	TR201802928T4 (pt)
TW (2)	TWI515204B (pt)
UA (1)	UA107557C2 (pt)
UY (1)	UY31210A1 (pt)
WO (1)	WO2009009407A1 (pt)
ZA (1)	ZA200909107B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160279239A1 (en)	2011-05-02	2016-09-29	Immunomedics, Inc.	Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en)	2011-05-02	2016-12-08	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
UA107557C2 (xx) *	2007-07-06	2015-01-26		Композиція антитіла офатумумабу
JP2010532790A (ja) *	2007-07-06	2010-10-14	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	抗体処方
EP3409289B1 (en)	2010-02-26	2020-09-30	Novo Nordisk A/S	Stable antibody containing compositions
CN102939098B (zh)	2010-03-01	2016-08-03	拜耳医药保健有限公司	针对组织因子途径抑制剂(tfpi)的优化的单克隆抗体
BR112012030139A2 (pt)	2010-05-28	2017-06-13	Novo Nordisk As	composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservante
JP2014510152A (ja) *	2011-04-07	2014-04-24	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	粘度が低減された処方物
UA116189C2 (uk)	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CA2831572C (en)	2011-05-02	2019-11-26	Immunomedics, Inc.	Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CA3051418C (en) *	2011-05-02	2021-05-18	Millennium Pharmaceuticals, Inc.	Methods of treating inflammatory bowel disease
UY34105A (es) *	2011-06-03	2012-07-31	Lg Life Sciences Ltd	Formulación líquida estable de etanercept
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
US10117823B2 (en) *	2013-03-12	2018-11-06	Primal Therapies, Inc.	Dental composition comprising chelator and base
EP2805730A1 (en) *	2013-05-21	2014-11-26	Bergen Teknologioverforing AS	Nitric oxide donor for the treatment of chronic fatigue syndrome
WO2015162504A1 (en)	2014-04-23	2015-10-29	Novartis Ag	Novel dosing and uses of ofatumumab
WO2016189491A1 (en) *	2015-05-28	2016-12-01	Glaxosmithkline Intellectual Property Development Limited	Novel formulation
AU2017213775A1 (en) *	2016-02-03	2018-08-16	Outlook Therapeutics, Inc.	Buffer formulations for enhanced antibody stability
ES2954259T3 (es)	2016-08-15	2023-11-21	Novartis Ag	Regímenes y métodos de tratamiento de la esclerosis múltiple utilizando ofatumumab
JPWO2018179138A1 (ja) *	2017-03-29	2020-02-06	持田製薬株式会社	抗体含有液体製剤
WO2018187074A1 (en)	2017-04-03	2018-10-11	Immunomedics, Inc.	Subcutaneous administration of antibody-drug conjugates for cancer therapy
WO2018204374A1 (en)	2017-05-02	2018-11-08	Merck Sharp & Dohme Corp.	Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3033195A1 (en) *	2018-02-09	2019-08-09	Ecolab Usa Inc.	Flowability testing systems and methods
LT3864053T (lt)	2019-09-11	2023-09-11	Novartis Ag	Rms gydymas, pakeičiant terapiją
KR20220062027A (ko)	2019-09-11	2022-05-13	노파르티스 아게	오파투무맙-치료된 환자에서의 다발성 경화증 이외의 병태의 관리
CN112675126A (zh) *	2019-10-18	2021-04-20	百奥泰生物制药股份有限公司	抗cd20抗体制剂及其应用
AU2021253674A1 (en)	2020-04-09	2022-11-03	Novartis Ag	Ofatumumab for treating MS while maintaining serum IgG
JP7057954B2 (ja) *	2020-09-03	2022-04-21	国立大学法人大阪大学	改善された保存安定性を有するタンパク質含有液体製剤
KR20230170923A (ko)	2021-04-14	2023-12-19	노파르티스 아게	아시아인 환자들에서 ms 치료용 오파투무맙
KR20240046200A (ko)	2021-08-16	2024-04-08	노파르티스 아게	소아 ms 치료를 위한 오파투무맙
WO2023204554A1 (ko) *	2022-04-20	2023-10-26	주식회사 알토스바이오로직스	오크렐리주맙을 포함하는 약학적 조성물과 그의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4816401A (en) *	1985-09-09	1989-03-28	University Of Rochester	Serum free cell culture medium
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de)	1991-11-25	2001-11-15	Enzon Inc	Multivalente antigen-bindende proteine
WO1998056418A1 (en) *	1997-06-13	1998-12-17	Genentech, Inc.	Stabilized antibody formulation
CA2386228A1 (en) *	1999-10-04	2001-04-12	Chiron Corporation	Stabilized liquid pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi) polypeptides
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
AU2003208415B2 (en)	2002-02-14	2009-05-28	Immunomedics, Inc.	Anti-CD20 antibodies and fusion proteins thereof and methods of use
JP4583762B2 (ja) *	2002-02-27	2010-11-17	イミュネックス・コーポレーション	ポリペプチド製剤
CN1671741A (zh) *	2002-06-21	2005-09-21	拜奥根Idec公司	浓缩抗体的缓冲剂制剂及其使用方法
NZ581541A (en) *	2002-10-17	2011-07-29	Genmab As	Human monoclonal antibodies against CD20
ATE527278T1 (de) *	2002-12-16	2011-10-15	Genmab As	Humane monoklonale antikörper gegen interleukin 8 (il-8)
US8084582B2 (en) *	2003-03-03	2011-12-27	Xencor, Inc.	Optimized anti-CD20 monoclonal antibodies having Fc variants
AR044388A1 (es)	2003-05-20	2005-09-07	Applied Molecular Evolution	Moleculas de union a cd20
EP1740946B1 (en)	2004-04-20	2013-11-06	Genmab A/S	Human monoclonal antibodies against cd20
DOP2006000029A (es) *	2005-02-07	2006-08-15	Genentech Inc	Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
DK2620450T3 (en) *	2005-03-08	2019-02-04	Pfizer Prod Inc	Antibody Compositions against CTLA-4
JP2009510046A (ja) *	2005-09-30	2009-03-12	メドイミューン・リミテッド	インターロイキン−１３抗体組成物
JP2010532790A (ja) *	2007-07-06	2010-10-14	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	抗体処方
UA107557C2 (xx) *	2007-07-06	2015-01-26		Композиція антитіла офатумумабу

2008
- 2008-03-07 UA UAA201001165A patent/UA107557C2/ru unknown
- 2008-07-03 LT LTEP15155712.1T patent/LT2889310T/lt unknown
- 2008-07-03 KR KR1020107000148A patent/KR20100038092A/ko not_active Application Discontinuation
- 2008-07-03 US US12/667,890 patent/US20110020328A1/en not_active Abandoned
- 2008-07-03 EA EA201070105A patent/EA017994B1/ru not_active IP Right Cessation
- 2008-07-03 AU AU2008275278A patent/AU2008275278B2/en active Active
- 2008-07-03 BR BR122020026978-2A patent/BR122020026978B1/pt active IP Right Grant
- 2008-07-03 PT PT87813234T patent/PT2170388T/pt unknown
- 2008-07-03 DK DK08781323.4T patent/DK2170388T3/en active
- 2008-07-03 DK DK15155712.1T patent/DK2889310T3/en active
- 2008-07-03 BR BRPI0814003-0A patent/BRPI0814003B1/pt active IP Right Grant
- 2008-07-03 KR KR1020157019741A patent/KR101670454B1/ko active IP Right Grant
- 2008-07-03 EP EP15155712.1A patent/EP2889310B1/en active Active
- 2008-07-03 SI SI200831928T patent/SI2889310T1/en unknown
- 2008-07-03 HU HUE15155712A patent/HUE038501T2/hu unknown
- 2008-07-03 PT PT151557121T patent/PT2889310T/pt unknown
- 2008-07-03 JP JP2010516158A patent/JP5529017B2/ja active Active
- 2008-07-03 NO NO15155712A patent/NO2889310T3/no unknown
- 2008-07-03 TR TR2018/02928T patent/TR201802928T4/tr unknown
- 2008-07-03 LT LTEP08781323.4T patent/LT2170388T/lt unknown
- 2008-07-03 MX MX2010000017A patent/MX2010000017A/es active IP Right Grant
- 2008-07-03 WO PCT/US2008/069125 patent/WO2009009407A1/en active Application Filing
- 2008-07-03 NZ NZ582250A patent/NZ582250A/en unknown
- 2008-07-03 CA CA2692681A patent/CA2692681C/en active Active
- 2008-07-03 SI SI200831738A patent/SI2170388T1/sl unknown
- 2008-07-03 ES ES08781323.4T patent/ES2610821T3/es active Active
- 2008-07-03 HU HUE08781323A patent/HUE031288T2/hu unknown
- 2008-07-03 PL PL08781323T patent/PL2170388T3/pl unknown
- 2008-07-03 ES ES15155712.1T patent/ES2663504T3/es active Active
- 2008-07-03 JO JOP/2008/0312A patent/JO3219B1/ar active
- 2008-07-03 PL PL15155712T patent/PL2889310T3/pl unknown
- 2008-07-03 EP EP08781323.4A patent/EP2170388B1/en active Active
- 2008-07-03 CN CN200880105866.1A patent/CN101820912B/zh active Active
- 2008-07-04 PE PE2008001136A patent/PE20090738A1/es active IP Right Grant
- 2008-07-04 CL CL2008001984A patent/CL2008001984A1/es unknown
- 2008-07-04 AR ARP080102910A patent/AR067455A1/es unknown
- 2008-07-04 TW TW097125246A patent/TWI515204B/zh active
- 2008-07-04 TW TW104128324A patent/TWI612060B/zh active
- 2008-07-04 UY UY31210A patent/UY31210A1/es not_active Application Discontinuation
2009
- 2009-12-21 ZA ZA2009/09107A patent/ZA200909107B/en unknown
- 2009-12-24 IL IL202950A patent/IL202950A/en active IP Right Grant
- 2009-12-30 MA MA32460A patent/MA31471B1/fr unknown
- 2009-12-30 CO CO09149371A patent/CO6270340A2/es active IP Right Grant
2010
- 2010-01-05 DO DO2010000001A patent/DOP2010000001A/es unknown
- 2010-02-02 CR CR11249A patent/CR11249A/es unknown
- 2010-09-02 HK HK10108319.5A patent/HK1141979A1/zh unknown
- 2010-09-02 HK HK15108178.0A patent/HK1207652A1/xx unknown
2015
- 2015-02-19 US US14/625,881 patent/US20150158951A1/en not_active Abandoned
2017
- 2017-01-10 HR HRP20170033TT patent/HRP20170033T1/hr unknown
- 2017-01-12 CY CY20171100043T patent/CY1118419T1/el unknown
- 2017-08-29 AR ARP170102392A patent/AR109461A2/es not_active Application Discontinuation
2018
- 2018-03-14 HR HRP20180440TT patent/HRP20180440T1/hr unknown
- 2018-03-20 CY CY20181100325T patent/CY1120047T1/el unknown
2021
- 2021-09-13 NO NO2021036C patent/NO2021036I1/no unknown
- 2021-09-14 FR FR21C1040C patent/FR21C1040I1/fr active Active
- 2021-09-15 LT LTPA2021520C patent/LTPA2021520I1/lt unknown
- 2021-09-15 HU HUS2100038C patent/HUS2100038I1/hu unknown

Also Published As

Publication number	Publication date
AR109461A2 (es)	2018-12-12
BRPI0814003B1 (pt)	2021-06-15
HUE038501T2 (hu)	2018-10-29
ES2663504T3 (es)	2018-04-13
LT2170388T (lt)	2017-01-10
PT2170388T (pt)	2017-01-04
ES2610821T3 (es)	2017-05-03
WO2009009407A1 (en)	2009-01-15
ZA200909107B (en)	2012-12-27
TWI612060B (zh)	2018-01-21
CY1118419T1 (el)	2017-06-28
KR101670454B1 (ko)	2016-10-31
HRP20170033T1 (hr)	2017-03-24
TR201802928T4 (tr)	2018-03-21
NO2889310T3 (pt)	2018-05-19
CA2692681C (en)	2018-12-04
LTPA2021520I1 (pt)	2021-10-11
CL2008001984A1 (es)	2009-01-09
US20110020328A1 (en)	2011-01-27
UA107557C2 (xx)	2015-01-26
CY1120047T1 (el)	2018-12-12
IL202950A (en)	2014-05-28
CR11249A (es)	2010-03-08
IL202950A0 (en)	2011-08-01
PL2170388T3 (pl)	2017-06-30
CA2692681A1 (en)	2009-01-15
AU2008275278A1 (en)	2009-01-15
TW201623334A (zh)	2016-07-01
JP5529017B2 (ja)	2014-06-25
AR067455A1 (es)	2009-10-14
HUE031288T2 (hu)	2017-06-28
HK1141979A1 (zh)	2010-11-26
UY31210A1 (es)	2009-01-30
DK2889310T3 (en)	2018-03-26
EP2170388B1 (en)	2016-10-12
SI2170388T1 (sl)	2017-01-31
EP2889310B1 (en)	2017-12-20
DOP2010000001A (es)	2010-01-31
EP2170388A4 (en)	2011-07-06
MA31471B1 (fr)	2010-06-01
PL2889310T3 (pl)	2018-06-29
EA201070105A1 (ru)	2010-08-30
JO3219B1 (ar)	2018-03-08
DK2170388T3 (en)	2017-01-16
KR20150088335A (ko)	2015-07-31
HK1207652A1 (en)	2016-02-19
CN101820912A (zh)	2010-09-01
EP2889310A1 (en)	2015-07-01
CO6270340A2 (es)	2011-04-20
HRP20180440T1 (hr)	2018-04-20
AU2008275278B2 (en)	2011-04-14
CN101820912B (zh)	2014-03-12
PT2889310T (pt)	2018-03-26
MX2010000017A (es)	2010-04-07
PE20090738A1 (es)	2009-07-18
NZ582250A (en)	2012-04-27
US20150158951A1 (en)	2015-06-11
TW200914466A (en)	2009-04-01
EP2170388A1 (en)	2010-04-07
JP2011526880A (ja)	2011-10-20
NO2021036I1 (no)	2021-09-13
SI2889310T1 (en)	2018-04-30
KR20100038092A (ko)	2010-04-12
BR122020026978B1 (pt)	2021-09-28
FR21C1040I1 (fr)	2021-11-19
EA017994B1 (ru)	2013-04-30
HUS2100038I1 (hu)	2021-10-28
LT2889310T (lt)	2018-03-26
TWI515204B (zh)	2016-01-01

Legal Events

Date	Code	Title	Description
2017-02-21	B25A	Requested transfer of rights approved	Owner name: NOVARTIS PHARMA AG (CH)
2017-03-07	B25A	Requested transfer of rights approved	Owner name: NOVARTIS AG (CH)
2017-03-28	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-01-29	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-05-14	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2020-10-06	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-04-06	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-06-15	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/07/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

Publication	Publication Date	Title
CY2019004I1 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0814003A2 (pt)	2015-02-03	Formulações de anticorpo
BRPI0814252A2 (pt)	2015-04-14	Formulações de anticorpo
BRPI0820819A2 (pt)	2015-06-16	Formulação de anticorpos
BRPI0922730A2 (pt)	2018-11-06	formulação de anticorpo
BRPI0807453A2 (pt)	2014-05-20	Preparação sólida
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
ATE501136T1 (de)	2011-03-15	Imidazopyridinone
EP2173163A4 (en)	2010-12-08	ANTIBODY FORMULATIONS
ATE514696T1 (de)	2011-07-15	Diphenyl-dihydro-imidazopyridinone
BRPI0814188A2 (pt)	2014-10-14	Formulações
DK2125048T3 (da)	2014-10-13	Præparat
BRPI0817427A2 (pt)	2015-06-16	Anticorpo anti-bst2
BRPI0814519A2 (pt)	2014-09-30	Organopolissiloxano
BRPI0811451A2 (pt)	2014-11-04	Exopolissacarídeo
BRPI0812840A2 (pt)	2014-12-09	2-imidazolinas
BRPI0815547A2 (pt)	2015-02-10	Depsipeptídeos cícliocos
AT505058A3 (de)	2008-12-15	Türschliesssystem
BRPI0812994A2 (pt)	2014-12-23	Microbiocidas
BRPI0819765A2 (pt)	2015-05-05	Conjugados de anticorpos anti-rg-1
EP2167635A4 (en)	2010-06-30	ANTIBODY FORMULATIONS
AT504425B8 (de)	2008-09-15	Portioniersteuerung
TH110653B (th)	2011-10-06	P-แคดฮีรินแอนติบอดี
FI7971U1 (fi)	2008-08-14	Muotti
FI7706U1 (fi)	2007-11-30	Muotti